AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 12514144 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (control, equal volume infused intravenously over 20 min)
Number of subjects: 59
Study 10376163 — intervention group
Group type: EXPERIMENTAL
Intervention: Diary recording using palmtop computers for 10 consecutive weeks
Number of subjects: 56
Study 9016423 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardized sign-out card
Number of subjects: 0
Study 1510006 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.05 mg/kg diltiazem
Number of subjects: 87
Study 1510006 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.15 mg/kg diltiazem
Number of subjects: 87
Study 1510006 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.25 mg/kg diltiazem
Number of subjects: 87
Study 1510006 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.45 mg/kg diltiazem
Number of subjects: 87
Study 1510006 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 87
Study 1510006 — intervention group
Group type: EXPERIMENTAL
Intervention: Diltiazem (0.15 to 0.45 mg/kg)
Number of subjects: 87
Study 1510006 — intervention group
Group type: EXPERIMENTAL
Intervention: Diltiazem
Number of subjects: 87
Study 6090367 — intervention group
Group type: EXPERIMENTAL
Intervention: MDF (6141 cGy, 69 fractions, 4 1/2 weeks, at 89 cGy every 4 hours 3 times daily)
Number of subjects: 128
Study 6090367 — intervention group
Group type: EXPERIMENTAL
Intervention: MDF plus MISO (1.25 gm/M2 three times weekly for the first 3 weeks)
Number of subjects: 128
Study 6090367 — intervention group
Group type: COMPARATOR
Intervention: CF (5800 cGy, 30 fractions, 6 weeks)
Number of subjects: 128
Study 6090367 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose MDF (7120 cGy, 80 fractions, 5 1/2 weeks, at 89 cGy per fraction every 4 hours 3 times daily)
Number of subjects: 128
Study 31783804 — intervention group
Group type: EXPERIMENTAL
Intervention: Subjects < 50 years
Number of subjects: 45
Study 31783804 — intervention group
Group type: COMPARATOR
Intervention: Subjects ≥ 50 years
Number of subjects: 45
Study 29517274 — intervention group
Group type: EXPERIMENTAL
Intervention: PowerScope
Number of subjects: 28
Study 29517274 — intervention group
Group type: COMPARATOR
Intervention: Forsus
Number of subjects: 28
Study 29517274 — intervention group
Group type: EXPERIMENTAL
Intervention: Both PowerScope and Forsus
Number of subjects: 28
Study 27652585 — intervention group
Group type: EXPERIMENTAL
Intervention: Sham feeding with gum chewing (two pieces of xylitol flavored gum for 15 minutes, three times a day after extubation until oral nutrition was tolerated)
Number of subjects: 59
Study 24964348 — intervention group
Group type: EXPERIMENTAL
Intervention: Setipiprant 1000 mg b.i.d. for 5 days
Number of subjects: 18
Study 24964348 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 21979440 — intervention group
Group type: EXPERIMENTAL
Intervention: 60 g glucose dose after an overnight fast
Number of subjects: 0
Study 21979440 — intervention group
Group type: EXPERIMENTAL
Intervention: 25 g glucose dose after a 2-hour fast
Number of subjects: 0
Study 19496710 — intervention group
Group type: EXPERIMENTAL
Intervention: Sorafenib (400 mg twice daily)
Number of subjects: 0
Study 19496710 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 17311061 — intervention group
Group type: EXPERIMENTAL
Intervention: TPN with glutamine (0.3 g/kg/days)
Number of subjects: 40
Study 17311061 — intervention group
Group type: COMPARATOR
Intervention: Standard TPN (control group)
Number of subjects: 40
Study 15738301 — intervention group
Group type: COMPARATOR
Intervention: Hypoxia at rest
Number of subjects: 37
Study 15738301 — intervention group
Group type: COMPARATOR
Intervention: Normoxic exercise
Number of subjects: 37
Study 15738301 — intervention group
Group type: COMPARATOR
Intervention: Hypoxic exercise
Number of subjects: 37
Study 15738301 — intervention group
Group type: EXPERIMENTAL
Intervention: Sensitivity and specificity testing
Number of subjects: 37
Study 15738301 — intervention group
Group type: EXPERIMENTAL
Intervention: Multivariate analysis of hypoxic ventilatory response and lung function parameters
Number of subjects: 37
Study 15738301 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulmonary artery systolic pressure measurements
Number of subjects: 37
Study 12533272 — intervention group
Group type: EXPERIMENTAL
Intervention: Epoetin alfa
Number of subjects: 0
Study 12533272 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 9842756 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual modality (below eye level)
Number of subjects: 12
Study 9842756 — intervention group
Group type: EXPERIMENTAL
Intervention: Tactile modality (below eye level)
Number of subjects: 12
Study 9842756 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual and tactile modalities (above eye level)
Number of subjects: 12
Study 7727100 — intervention group
Group type: EXPERIMENTAL
Intervention: Superior corneal incision
Number of subjects: 39
Study 7727100 — intervention group
Group type: EXPERIMENTAL
Intervention: Temporal corneal incision
Number of subjects: 39
Study 2643904 — intervention group
Group type: EXPERIMENTAL
Intervention: Sustained-release theophylline (THEO)
Number of subjects: 26
Study 2643904 — intervention group
Group type: COMPARATOR
Intervention: Inhaled bitolterol (BITOL)
Number of subjects: 26
Study 1146718 — intervention group
Group type: EXPERIMENTAL
Intervention: Micronor (progestogen type oral contraceptive)
Number of subjects: 13
Study 1146718 — intervention group
Group type: EXPERIMENTAL
Intervention: Ortho‐Novum SQ (sequential type oral contraceptive)
Number of subjects: 13
Study 1146718 — intervention group
Group type: COMPARATOR
Intervention: Control cycle (no oral contraceptives)
Number of subjects: 13
Study 1146718 — intervention group
Group type: EXPERIMENTAL
Intervention: Micronor and Ortho‐Novum SQ
Number of subjects: 13
Study 30324895 — intervention group
Group type: EXPERIMENTAL
Intervention: ART-experienced patients
Number of subjects: 40
Study 30324895 — intervention group
Group type: COMPARATOR
Intervention: ART-naïve patients
Number of subjects: 40
Study 30324895 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparison of sTNFR1 and sTNFR2 levels
Number of subjects: 40
Study 30324895 — intervention group
Group type: EXPERIMENTAL
Intervention: Different ART combinations
Number of subjects: 40
Study 31682574 — intervention group
Group type: EXPERIMENTAL
Intervention: Culturally safe eHealth research practices
Number of subjects: 0
Study 31682574 — intervention group
Group type: COMPARATOR
Intervention: DREAM-GLOBAL RCT
Number of subjects: 0
Study 28032550 — intervention group
Group type: EXPERIMENTAL
Intervention: Optilene LP mesh (OLP group)
Number of subjects: 145
Study 28032550 — intervention group
Group type: COMPARATOR
Intervention: self-gripping Parietex ProGrip mesh (PPG group)
Number of subjects: 145
Study 25399314 — intervention group
Group type: COMPARATOR
Intervention: Moderate-intensity exercise
Number of subjects: 14
Study 25399314 — intervention group
Group type: COMPARATOR
Intervention: High-intensity exercise
Number of subjects: 14
Study 25399314 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual stimulation
Number of subjects: 14
Study 23816814 — intervention group
Group type: EXPERIMENTAL
Intervention: levocetirizine hydrochloride 5 mg (Xyzal®) administered on day 8 after placebo for 7 days (treatment B)
Number of subjects: 50
Study 23816814 — intervention group
Group type: COMPARATOR
Intervention: levocetirizine hydrochloride 5 mg (Xyzal®) administered for 8 days (treatment C)
Number of subjects: 50
Study 23816814 — intervention group
Group type: COMPARATOR
Intervention: placebo administered for 8 days (treatment A)
Number of subjects: 50
Study 21188411 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyper‐caloric fat‐rich diet (HFD) for 6 weeks
Number of subjects: 7
Study 19267954 — intervention group
Group type: EXPERIMENTAL
Intervention: HP meal with 0.6% MSG and 0.25% IMP-5
Number of subjects: 22
Study 19267954 — intervention group
Group type: EXPERIMENTAL
Intervention: HP meal with MSG only
Number of subjects: 22
Study 19267954 — intervention group
Group type: EXPERIMENTAL
Intervention: HP meal with no additives
Number of subjects: 22
Study 19267954 — intervention group
Group type: COMPARATOR
Intervention: Water (control)
Number of subjects: 22
Study 19267954 — intervention group
Group type: COMPARATOR
Intervention: Sham-fed meal 2 (oral-stimulation)
Number of subjects: 22
Study 17224218 — intervention group
Group type: EXPERIMENTAL
Intervention: MMR vaccine alone
Number of subjects: 0
Study 17224218 — intervention group
Group type: EXPERIMENTAL
Intervention: MMR vaccine in combination with varicella (MMR and V)
Number of subjects: 0
Study 17224218 — intervention group
Group type: EXPERIMENTAL
Intervention: Delayed MMR vaccination (42 days)
Number of subjects: 0
Study 17224218 — intervention group
Group type: COMPARATOR
Intervention: Cytokine responses to phytohaemagglutinin and tetanus toxoid
Number of subjects: 0
Study 15169694 — intervention group
Group type: EXPERIMENTAL
Intervention: Risperidone (1‐6 mg/day)
Number of subjects: 259
Study 15169694 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 259
Study 11401073 — intervention group
Group type: EXPERIMENTAL
Intervention: Animal farmers (cattle, pigs, poultry, sheep)
Number of subjects: 6156
Study 9572210 — intervention group
Group type: EXPERIMENTAL
Intervention: Medroxyprogesterone acetate 2.5 mg + E1 sulfate 1.25 mg
Number of subjects: 568
Study 9572210 — intervention group
Group type: EXPERIMENTAL
Intervention: Medroxyprogesterone acetate 5 mg + E1 sulfate 1.25 mg
Number of subjects: 568
Study 9572210 — intervention group
Group type: EXPERIMENTAL
Intervention: Medroxyprogesterone acetate 10 mg + E1 sulfate 1.25 mg
Number of subjects: 568
Study 7999348 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral treatment of depression in dementia patients
Number of subjects: 0
Study 2741997 — intervention group
Group type: EXPERIMENTAL
Intervention: Sensorimotor integrative treatment
Number of subjects: 90
Study 2741997 — intervention group
Group type: COMPARATOR
Intervention: Functional treatment
Number of subjects: 90
Study 790561 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol
Number of subjects: 12
Study 790561 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 12
Study 790561 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 30101636 — intervention group
Group type: EXPERIMENTAL
Intervention: Methotrexate and intra-articular glucocorticoids
Number of subjects: 120
Study 30101636 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment, biologics, and no treatment
Number of subjects: 120
Study 29947443 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual Meaning‐Centered Psychotherapy (IMCP)
Number of subjects: 223
Study 29947443 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with UB
Number of subjects: 223
Study 29947443 — intervention group
Group type: EXPERIMENTAL
Intervention: UB-related distress
Number of subjects: 223
Study 29947443 — intervention group
Group type: EXPERIMENTAL
Intervention: UB themes
Number of subjects: 223
Study 26580483 — intervention group
Group type: EXPERIMENTAL
Intervention: Foraminal enlargement (FE)
Number of subjects: 70
Study 26580483 — intervention group
Group type: COMPARATOR
Intervention: Conventional nonforaminal enlargement (NFE)
Number of subjects: 70
Study 25246569 — intervention group
Group type: EXPERIMENTAL
Intervention: High-resolution fMRI during a task taxing mnemonic discrimination of object identity
Number of subjects: 0
Study 25246569 — intervention group
Group type: EXPERIMENTAL
Intervention: High-resolution fMRI during a task taxing mnemonic discrimination of spatial location
Number of subjects: 0
Study 25246569 — intervention group
Group type: EXPERIMENTAL
Intervention: High-resolution fMRI during a task taxing mnemonic discrimination
Number of subjects: 0
Study 22211956 — intervention group
Group type: EXPERIMENTAL
Intervention: Alfuzosin 10 mg
Number of subjects: 100
Study 22211956 — intervention group
Group type: EXPERIMENTAL
Intervention: Alfuzosin 10 mg + Sildenafil 50 mg
Number of subjects: 100
Study 20304413 — intervention group
Group type: EXPERIMENTAL
Intervention: High protein, low carbohydrate diet (20 g/d)
Number of subjects: 46
Study 20304413 — intervention group
Group type: COMPARATOR
Intervention: Low fat diet (30% of calories)
Number of subjects: 46
Study 17627237 — intervention group
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Number of subjects: 84
Study 17627237 — intervention group
Group type: COMPARATOR
Intervention: Cyclosporine
Number of subjects: 84
Study 16256868 — intervention group
Group type: EXPERIMENTAL
Intervention: TriActiv System (Kensey Nash Corp.)
Number of subjects: 631
Study 16256868 — intervention group
Group type: COMPARATOR
Intervention: Control group (Guardwire System or Filterwire EX)
Number of subjects: 631
Study 12821836 — intervention group
Group type: EXPERIMENTAL
Intervention: Generic sodium stibogluconate
Number of subjects: 0
Study 12821836 — intervention group
Group type: EXPERIMENTAL
Intervention: Miltefosine
Number of subjects: 0
Study 12821836 — intervention group
Group type: EXPERIMENTAL
Intervention: Liposomal amphotericin B
Number of subjects: 0
Study 12821836 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluconazole
Number of subjects: 0
Study 12821836 — intervention group
Group type: EXPERIMENTAL
Intervention: Sitamaquine (WR6026)
Number of subjects: 0
Study 12821836 — intervention group
Group type: EXPERIMENTAL
Intervention: AmBisome
Number of subjects: 0
Study 10504890 — intervention group
Group type: EXPERIMENTAL
Intervention: Peg-hole assembly task (manual)
Number of subjects: 0
Study 10504890 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual character identification task (visual)
Number of subjects: 0
Study 10504890 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined manual and visual tasks
Number of subjects: 0
Study 8758170 — intervention group
Group type: EXPERIMENTAL
Intervention: Thiopentone 5 mg.kg‐1 preceded by 40 mg of topical lignocaine spray
Number of subjects: 90
Study 8758170 — intervention group
Group type: COMPARATOR
Intervention: Propofol 2.5 mg.kg‐1 alone
Number of subjects: 90
Study 2206072 — intervention group
Group type: EXPERIMENTAL
Intervention: Prostaglandin E2 gel (2.5 mg)
Number of subjects: 69
Study 2206072 — intervention group
Group type: EXPERIMENTAL
Intervention: Prostaglandin E2 chip (3.0 mg)
Number of subjects: 69
Study 6791231 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg oral diazepam
Number of subjects: 0
Study 30816331 — intervention group
Group type: EXPERIMENTAL
Intervention: Augmented intensity post induction intensification (PII)
Number of subjects: 2057
Study 30816331 — intervention group
Group type: COMPARATOR
Intervention: Standard strength post induction intensification (PII)
Number of subjects: 2057
Study 30816331 — intervention group
Group type: EXPERIMENTAL
Intervention: Idarubicin/cyclophosphamide
Number of subjects: 2057
Study 30816331 — intervention group
Group type: COMPARATOR
Intervention: Weekly doxorubicin
Number of subjects: 2057
Study 28486551 — intervention group
Group type: EXPERIMENTAL
Intervention: Definitive chemoradiation (CRT)
Number of subjects: 267
Study 28486551 — intervention group
Group type: COMPARATOR
Intervention: Radical surgery
Number of subjects: 267
Study 26077176 — intervention group
Group type: EXPERIMENTAL
Intervention: Sapropterin (5 mg/kg/day increased to 10 mg/kg on day 8)
Number of subjects: 40
Study 26077176 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 24717838 — intervention group
Group type: EXPERIMENTAL
Intervention: Brivaracetam single dose (2.5-100 mg)
Number of subjects: 80
Study 24717838 — intervention group
Group type: EXPERIMENTAL
Intervention: Brivaracetam multiple dose (2.5-50 mg twice daily)
Number of subjects: 80
Study 24717838 — intervention group
Group type: EXPERIMENTAL
Intervention: Brivaracetam in homozygous extensive metabolizers (EM)
Number of subjects: 80
Study 24717838 — intervention group
Group type: EXPERIMENTAL
Intervention: Brivaracetam in heterozygous EM
Number of subjects: 80
Study 24717838 — intervention group
Group type: EXPERIMENTAL
Intervention: Brivaracetam in poor metabolizers (PM)
Number of subjects: 80
Study 24717838 — intervention group
Group type: EXPERIMENTAL
Intervention: Brivaracetam in PM participants
Number of subjects: 80
Study 22791079 — intervention group
Group type: EXPERIMENTAL
Intervention: Biotin (1 mg/day)
Number of subjects: 14
Study 20643186 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate (20mg)
Number of subjects: 0
Study 20643186 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 17013636 — intervention group
Group type: EXPERIMENTAL
Intervention: Active tea treatment (n = 37)
Number of subjects: 75
Study 17013636 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 38)
Number of subjects: 75
Study 15839961 — intervention group
Group type: EXPERIMENTAL
Intervention: Circular stapled haemorrhoidectomy under local anaesthesia
Number of subjects: 60
Study 15839961 — intervention group
Group type: COMPARATOR
Intervention: Circular stapled haemorrhoidectomy under regional anaesthesia
Number of subjects: 60
Study 11940691 — intervention group
Group type: EXPERIMENTAL
Intervention: Nimesulide 100 mg by mouth twice daily
Number of subjects: 40
Study 11940691 — intervention group
Group type: COMPARATOR
Intervention: Matching placebo
Number of subjects: 40
Study 9789918 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention methods for community trials
Number of subjects: 0
Study 9789918 — intervention group
Group type: EXPERIMENTAL
Intervention: Permutation tests
Number of subjects: 0
Study 9789918 — intervention group
Group type: COMPARATOR
Intervention: Standard Mantel-Haenszel methods
Number of subjects: 0
Study 7631673 — intervention group
Group type: COMPARATOR
Intervention: Observation phase (no treatment)
Number of subjects: 1260
Study 7631673 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment phase (clindamycin 300 mg orally twice daily for 7 days)
Number of subjects: 1260
Study 7631673 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment phase (clindamycin for bacterial vaginosis and trichomoniasis)
Number of subjects: 1260
Study 2483979 — intervention group
Group type: EXPERIMENTAL
Intervention: aprotinin (2 x 10(6) KIU in the pump prime)
Number of subjects: 23
Study 2483979 — intervention group
Group type: COMPARATOR
Intervention: placebo treatment
Number of subjects: 23
Study 2483979 — intervention group
Group type: EXPERIMENTAL
Intervention: aprotinin
Number of subjects: 23
Study 7412430 — intervention group
Group type: EXPERIMENTAL
Intervention: Attitude instrument for self-care
Number of subjects: 245
Study 30517071 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive preventive protocol (subgroups A1, B1, C1) including topical application of fluoride, brushing with 5000-ppm fluoride toothpaste, use of amorphous calcium phosphate-casein phosphopeptide, applications of sealants for occlusal lesions (ICDAS code 2), and minimal resin restorations for occlusal lesions (ICDAS code 3)
Number of subjects: 44
Study 30517071 — intervention group
Group type: COMPARATOR
Intervention: Instructions in oral hygiene (subgroups A2, B2, C2)
Number of subjects: 44
Study 30517071 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive preventive protocol (subgroup C1)
Number of subjects: 44
Study 30517071 — intervention group
Group type: COMPARATOR
Intervention: Instructions in oral hygiene (subgroup C2)
Number of subjects: 44
Study 28291239 — intervention group
Group type: EXPERIMENTAL
Intervention: Cap assisted esophagogastroduodenoscopy (CA‐EGD)
Number of subjects: 101
Study 25826741 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrate supplementation (beetroot juice; 5 mm, 0.45 g nitrates per day for 3 days)
Number of subjects: 0
Study 25826741 — intervention group
Group type: COMPARATOR
Intervention: Control (Ringer solution)
Number of subjects: 0
Study 23404145 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic surgery (LS)
Number of subjects: 60
Study 23404145 — intervention group
Group type: COMPARATOR
Intervention: Open surgery (OS)
Number of subjects: 60
Study 21830407 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative transarterial chemoembolization (TACE)
Number of subjects: 257
Study 18722627 — intervention group
Group type: EXPERIMENTAL
Intervention: computer-delivered attentional retraining
Number of subjects: 24
Study 18722627 — intervention group
Group type: COMPARATOR
Intervention: sham training
Number of subjects: 24
Study 19286361 — intervention group
Group type: EXPERIMENTAL
Intervention: TPI 1020 (600mcg bid for 2 weeks, then 1200mcg bid for 1 week)
Number of subjects: 27
Study 19286361 — intervention group
Group type: COMPARATOR
Intervention: Budesonide (400mcg bid for 2 weeks, then 800mcg bid for 1 week)
Number of subjects: 27
Study 19286361 — intervention group
Group type: EXPERIMENTAL
Intervention: TPI 1020
Number of subjects: 27
Study 19286361 — intervention group
Group type: COMPARATOR
Intervention: Budesonide
Number of subjects: 27
Study 15814512 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous morphine infusion
Number of subjects: 0
Study 15814512 — intervention group
Group type: COMPARATOR
Intervention: Intravenous morphine infusion
Number of subjects: 0
Study 11970933 — intervention group
Group type: EXPERIMENTAL
Intervention: Cows' milk
Number of subjects: 1108
Study 11970933 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1108
Study 9796226 — intervention group
Group type: EXPERIMENTAL
Intervention: Fragmented presentation of highly typical items
Number of subjects: 0
Study 9796226 — intervention group
Group type: EXPERIMENTAL
Intervention: Fragmented items preceded by other fragmented items
Number of subjects: 0
Study 9796226 — intervention group
Group type: EXPERIMENTAL
Intervention: General presentation form of items
Number of subjects: 0
Study 7611178 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluorescence in situ hybridization (FISH)
Number of subjects: 40
Study 7611178 — intervention group
Group type: COMPARATOR
Intervention: Cytology
Number of subjects: 40
Study 2694339 — intervention group
Group type: COMPARATOR
Intervention: Chloramphenicol (total daily dosage, 2 g) plus placebo
Number of subjects: 71
Study 2694339 — intervention group
Group type: EXPERIMENTAL
Intervention: Furazolidone (total daily dosage, 800 mg) plus placebo
Number of subjects: 71
Study 2694339 — intervention group
Group type: COMPARATOR
Intervention: Chloramphenicol
Number of subjects: 71
Study 2694339 — intervention group
Group type: EXPERIMENTAL
Intervention: Furazolidone
Number of subjects: 71
Study 846510 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyaluronidase treatment (administered intravenously after the first electrocardiogram and every six hours for 48 hours)
Number of subjects: 91
Study 846510 — intervention group
Group type: COMPARATOR
Intervention: Control group (no hyaluronidase treatment)
Number of subjects: 91
Study 846510 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyaluronidase treatment
Number of subjects: 91
Study 846510 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 91